ProMIS Neurosciences (PMN) Restructuring Costs (2024 - 2026)
ProMIS Neurosciences' (PMN) quarterly Restructuring Costs came in at $1.1 million in Q1 2026, up 6.08% YoY from $1.0 million in Q1 2025, and up 22.59% on a QoQ basis from $876352.0 in Q4 2025.
ProMIS Neurosciences (PMN) Restructuring Costs (2024 - 2026) Analysis & Trends
ProMIS Neurosciences (PMN) has 3 years of Restructuring Costs data on file, last reported at $1.1 million in Q1 2026.
- Quarterly Restructuring Costs rose 6.08% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (down 1.65% YoY) and the FY2025 annual result came in at $4.0 million, down 9.88% from the prior year.
- Restructuring Costs advanced to $1.1 million in Q1 2026, from $876352.0 in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $1.3 million in Q1 2024 to a low of $860124.0 in Q2 2025.
- A 3-year average of $1.1 million and a median of $1.0 million in 2025 frame the typical range for Restructuring Costs.
- Annual changes were most pronounced in 2025 — Restructuring Costs declined 23.39% — and 2026, when it advanced 6.08%.
- Tracing PMN's Restructuring Costs over 3 years: stood at $917894.0 in 2024, then fell by 4.53% to $876352.0 in 2025, then increased by 22.59% to $1.1 million in 2026.
- The last three Restructuring Costs figures came in at $1.1 million (Q1 2026), $876352.0 (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | ProMIS Neurosciences | 132.34 Mn | 78.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.25 Mn |
| Mar 31, 2026 | 1.07 Mn |
| Dec 31, 2025 | 876,352.00 |
| Sep 30, 2025 | 1.25 Mn |
| Jun 30, 2025 | 860,124.00 |
| Mar 31, 2025 | 1.01 Mn |
| Dec 31, 2024 | 917,894.00 |
| Sep 30, 2024 | 1.29 Mn |
| Jun 30, 2024 | 909,201.00 |
| Mar 31, 2024 | 1.32 Mn |